Pargyline
| Clinical data | |
|---|---|
| Trade names | Eutonyl; Eutron |
| Other names | MO-911; A-19120; Lopac-P-8013; NSC-43798; N-Methyl-N-propargylbenzylamine |
| MedlinePlus | a682088 |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Metabolites | • N-Methylbenzylamine • N-Propargylbenzylamine • N-Methylpropargylamine • Benzylamine • Propiolaldehyde • Propargylamine • Benzaldehyde • Pargyline-N-oxide |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.008.275 |
| Chemical and physical data | |
| Formula | C11H13N |
| Molar mass | 159.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pargyline, sold under the brand name Eutonyl among others, is a monoamine oxidase inhibitor (MAOI) medication which has been used to treat hypertension (high blood pressure) but is no longer marketed. It has also been studied as an antidepressant, but was never licensed for use in the treatment of depression. The drug is taken by mouth.
Side effects of pargyline include orthostatic hypotension among others. It has the potential for serious food and drug interactions with sympathomimetic agents like tyramine that can result in hypertensive crisis. Pargyline acts as a non-selective and irreversible inhibitor of the monoamine oxidases MAO-A and MAO-B. The exact mechanism of the hypotensive effects of pargyline and other MAOIs is unclear. Structurally, pargyline is a benzylamine derivative and is related to selegiline and clorgyline.
Pargyline was first described in 1960 and was introduced for medical use in 1963. It was available in the United States and the United Kingdom. The clinical use of pargyline was limited due to its side effects and interactions. The drug remained available in the United States as late as 2000. However, it was fully discontinued worldwide by 2007.